Where we at?, page-73

Hey buck, nothing legally stopping Bene from buying PAR, but we don't really know their finances / ability to spend. What are global sales of Elmiron, maybe $300m, what are global sales of cartrophen, that is also not easy to establish and what is their cut on those sales (their cut from PAR is rumoured to be 3% ish).
Sure PAR represents major growth for Bene if they can get over hurdles and make it to the big stage, but at circa 3% royalty (Par to Bene) that's only $30m on $1bn in sales (you can all model it out to your hearts content: $2500 per course, 400,000 courses p.a. = $1bn in sales etc etc).
My point is they can sit this out and watch this management either get lucky or continue to blunder. If they get lucky, then great, Bene is a beneficiary, if they CONTINUE to blunder then they could purchase the IP if they so desire and waltz over to J&J and see if they can redeem themselves from the Elmiron troubles with a new application.
Bene have had ample time to dig into their pockets and become a shareholder or loan money to support trials, but they haven't, no-one from inside the healthcare community (corporate or investor) has decided to financially support PAR.